summarize: strategic report highlights chairmans statement diurnal glance ceo qa markets business model strategy chief executives review financial review principal risks uncertainties corporate governance introduction corporate governance board directors corporate governance report remuneration report directors report statement directors responsibilities financial statements independent auditors report consolidated income statement consolidated statement comprehensive income consolidated balance sheet company balance  summarize: sheet consolidated company statements changes equity consolidated company cash flow statements notes financial statements notice annual general meeting form proxy committed addressing major unmet clinical patient needs hormone replacement initially developing marketing products rare orphan diseases congenital adrenal hyperplasia cah adrenal insufficiency ai. find diurnal.co.uk diurnal group plc _ annual report highlights operational primary endpoint successfully met european phase iii infacort registration summarize:  trial paediatric ai infacort paediatric use marketing authorisation puma submitted european medicines agency ema first patient dosed food matrix compatibility study intended form part us phase iii registration package infacortex expanded global patent estate first us patent granted inacort completed first phase establishing companys europea commercial infrastructure implemented commercial supply chain infacorts significant progress europeans phase iii trial chronocort cah patients enrolled financial operatin summarize: g loss.m.m reflecting increased investment support groups anticipated development cash cash equivalents held maturity financial assets june.m.m net cash used operating activities.m,m line boards expectations postperiod highlights line regulatory evaluation submitted responses day questions received ema following review infacort puma package submitted proposed phase iii pivotal us registration study design supporting data package chronocort us food drug administration fda expanded global patent estate  summarize: first us patent granted chronocort.m research development expenditure.m. infacort chronocortex latestage clinical development targeting indications cortisol deficiency infacortex completed phase iii clinical trial submitted marketing authorisation europe chronocorted currently undergoing phase iii Clinical trial europe. diurnal group plc _ annual report board changes governance diurnal strengthened board year appointment richard bungay chief financial officer. big markets programmes addressing estimate patie summarize: nts suffering cah across us europe believe translates total potential market m. paediatric ai market address infacort around patients europe similar number us giving potential market opportunity around m. whilst relatively small market infacortex important mark diurnals first commercial launch..bn estimated value hypogonadism market. complete phase iii trials infacax chronocort europe us. research development expenditure year.m.m. expenditure product development clinical costs increased period group s summarize: ubmitted infacort puma application ema continued progress chronocort phase iii registration trial europe. strategic report diurnal group plc _ annual report principal risks uncertainties manage risk management risk key responsibility board directors. group also orphan drug designation infacorts chronocortex us europe. membership june alan raymond chairman john goddard peter allen sam williams meetings held board membership executive director nonexecutive director audit committee remuneration committee nomin summarize: ation committee executive management team board independent nonexecutive director corporate governance diurnal group plc _ annual report richard ross mbbs md frcp chief scientific officer richard bungay bsc aca chief financial officer company secretary martin whitaker bsc phd chief executive officer peter allen ba aca nonexecautive chairman board directors right team deliver appointed july skills experience peter years experience senior board positions wide portfolio healthcare companies. roles director pha summarize: rma limited. roles director chroma therapeutics ltd nonexecutive director glide pharmaceutical technologies ltd. diurnal group plc _ annual report alan raymond bsc phd nonexecute director board representative finance wales john goddard ba fca mct independent nonexecutor director sam williams phd nonecutive Director board representative ip group plcs appointed november skills experience john distinguished career global pharmaceutical industry majority astrazeneca ltd executive vice president of strategic planning and strategic planning summarize:  business development. audit committee including audit committee report audit committee comprises four members nonexecutive directors john goddard chairman peter allen alan raymond sam williams. corporate governance diurnal group plc _ annual report corporate governance report continued audit committee meeting audit committee audit committee met four times review audit strategy plan full year results final results prior submission approval full board interim results prior submissions app summarize: roval full board audit strategy plan full year results. years annual general meeting held november details resolutions proposed meeting found notice meeting end annual report. behalf board peter allen chairman september corporate governance diurnal group plc _ annual report remuneration report introduction report sets remunerations policy operated group respect executive nonexecutive directors. corporate governance duurnal group bc _ Annual report remunation report continued directors remunerated audi summarize: ted remuneration directors held office periods ended june follows name basic salary fees bonus benefits compensation loss office total emoluments pension contributions total emolsuments pension liabilities executive martin whitaker richard bungay ian ardill richard ross nonexecutive peter allen john goddard alan raymond sam williams directors emolument include emolaires due directors diurnal group plc. directors share options awards directors holding office june following options outstanding ordinary sh summarize: ares date grantaward exercise price july granted year exercised lapsed june latest vesting date executive martin whitaker july option grant. directors interests share capital company date report shown directors report page. june market price companys shares pence per share market capitalisation approximately.m. behalf board alan raymond remuneration committee chairman september corporate governance diurnal group plc _ annual report directors report directors present report audited financial statements d summarize: iurnal group plc company subsidiary together group year ended june. research development year group spent.m.m continuing development product portfolio. directors served throughout financial year subsequently date signing financial statements except noted name title date appointment date resignation peter allen nonexecutive chairman martin whitaker chief executive officer richard bungay chief financial officer january ian ardill chief financial officers january richard ross chief scientific officer john g summarize: oddard nonexecutive director alan raymond nonexecute director sam williams nonexecutor director diurnal group plc _ annual report directors officers liability insurance company permitted companies act maintained insurance cover behalf directors indemnifying certain liabilities may incurred relation group. financial risk management description financial risk managing including use financial instruments group set note financial statements. behalf board richard bungay company secretary september corpora summarize: te governance diurnal group plc _ annual report statement directors responsibilities directors responsible preparing strategic report directors report group parent company financial statements accordance applicable law regulations. company law requires directors prepare group parent companies financial statements financial year. orphan drug designation patents knowhow trademarks see link strategy page see links strategy page infacort chronocort ditest tm case study diurnal groups plc - annual report financi summarize: al statements diurnal group plc _ annual report independent auditors report members diurnal Group plc opinion unmodified audited audited financial statement diurnal groups plc company year ended june comprise consolidated income statement consolidated statement comprehensive income consolidated balance sheet company balance sheet consolidated company statements changes equity consolidated company cash flow statements related notes including accounting policies note. nothing report information annual report directo summarize: rs responsible information presented annual report together financial statements. strategic report directors report based solely work information identified material misstatements strategic report Directors report opinion information given reports financial year consistent financial statements opinion reports prepared accordance companies act. consolidated statement comprehensive income year ended june year ended year ended lune june loss year diurnal group plc _ annual report consolidated balance sheet j summarize: une note noncurrent assets intangible assets property plant equipment current assets trade receivables held maturity financial assets cash cash equivalents total assets current liabilities trade payables noncurrent liabilities loans borrowings total liabilities net assets equity share capital share premium consolidation reserve reserve accumulated lossesretained earnings total equity financial statements approved board directors september signed behalf richard bungay director company registered number finan summarize: cial statements diurnal group plc _ annual report company balance sheet june note noncurrent assets investments amount owed subsidiary undertaking current assets trade receivables held maturity financial assets cash cash equivalents total assets current liabilities trade payables noncurrent liabilities loans borrowings total liabilities net assets equity share capital share premium reserve retained earnings total equity financial statements approved board directors september signed behalf richard bungay dir summarize: ector company registered number diurnal group plc _ annual report consolidated company statements changes equity year ended june group share capital share premium consolidation reserve reserve accumulated losses retained earnings total balance june loss year total comprehensive loss year equity settled share based payment transactions reduction capital issue shares cash costs charged share premium equity component convertible loan issue expenses convertible loan repurchase deferred shares total transactions summarize:  owners recorded directly equity balance june loss year total comprehensive loss year equity settled share based payment transactions issue shares cash total transactions owners recorded direct equity Balance june company share capital share premium reserve retained earnings total balance incorporation october loss yeartotal comprehensive loss years equity settled Share based payment deals issue shares acquisition reduction capital increase shares cash costs charged share premium equity component conv summarize: ertible loan issue expenses convertible loan repurchase deferred shares total transactions owners recorded directly equity balance june profit year total comprehensive profit year equity settled share based payment transactions issue shares cash total transactions owner recorded directly Equity balance junes profit loss year constituent total comprehensive loss year amounts shown line consolidated company statements changes equity. financial statements diurnal group plc _ annual report consolidated  summarize: company cash flow statements year ended june group company cash flows operating activities net cash used operating activities loss year end june year ended June year end June Year ended jUNE cash flows operations activities lossprofit year adjustments depreciation amortisation impairment sharebased payment financial income finance expenses taxation increase trade receivables increase amount owed subsidiary undertaking increase trade payables cash used operations interest paid tax received net cash to operating activities cash flows investing activities additions net cash flow operating activities summarize: rty plant equipment purchases held maturity financial assets disposal held maturity Financial assets loan subsidiary undertaking interest received net cash fromused investing activities cash flows financing activities net proceeds issue share capital repayment borrowings net proceeds use borrowings Net cash generated financing activities Net decreaseincrease cash cash equivalents cash cash equivalent start year cash cash cash and equivalents end year diurnal group plc _ annual report notes ﬁnancial statements cor summarize: porate information consolidated financial statements diurnal group plc subsidiary collectively group year ended june authorised issue accordance resolution directors september. financial statements Diurnal group Plc _ annual report notes ﬁnancial statements continued significant accounting policies basis preparation continued. diurnal Group plc_ annual report significant accounting procedures basis preparation continue. financial statement diurnal groups plc _ quarterly report notesﬁnsancial statements cont summarize: inued significant accounting policies basis preparation continued. expenses auditors remuneration loss year charging year ending june year ended june depreciation amortisation research development expenditure auditors reuneration fees payable company auditor audit parent company consolidated financial statements auditing accounts subsidiary pursuant legislation reporting companies act section conversion public limited company services transaction services fees relation ipo tax fees comparison ipo total audit summarize: ors remuneration number oneoff share option related noncash items totalling.m analysed following table year ended june year end june research development expenditure ifrs equity settled share based payment transactions noncash employer nic provision unapproved share options initial recognition historical liability administrative expenses expenses initial public offering oneoff ifrs Equity settled share bases payment transactions Noncash employee nic provision nonapproved shareoptions initial recognition  summarize: historical liability staff costs average number persons employed group including executive nonexecutive directors year analysed category follows year ended june number year ended June number research development administration nonexecute directors financial statements diurnal group plc _ annual report notes ﬁnancial statements continued staff costs continued aggregate remuneration including directors comprised year ended 2017 year end june year ended 2016 june wages salaries nonecutive director fees social security pensio summarize: n benefits share based payments see note details directors remuneration highest paid director found remunerations report. standard rate uk corporation tax reduced effect april giving rise effective rate tax year ended june.. loss per share year end june year ended lune loss year weighted average number shares basic diluted loss per per share pence per share. diurnal group plc _ annual report share based payment june group company two types share based pay awards share options including performance shar summarize: e awards deferred share bonus awards. financial statements diurnal group plc _ annual report notes ﬁnancial statements continued share based payments continued share options continued ifrs valuation share options issued ltip fair value services received return performance share awards restricted share awards market value option awards issued ltips excluding deferred bonus awards measured reference fair value share options granted. expected life average expected period exercise taken five years share option summarize: s shorter period share awards. measurement assumptions follows financial year ended deemed grant date may november september septur april april award type performance share performance share option share option option share award share price. expected option life years years years year years years. deemed number options deferred share bonus awards made respect financial year end june. exercisable end year total expense recognised share based payments follows year ended june year ended janune s summarize: hare options deferred share awards financial statements diurnal group plc _ annual report notes ﬁnancial statements continued financial instruments groups companys activities expose variety financial risks credit risk liquidity risk market risk including foreign currency risk interest rate risk. equity investments diurnal groups plc december following related parties purchased companys shares cash ip group plca subsidiaries ordinary shares finance wales subsidiaries shares richard ross shares peter allen sha summarize: res john goddard shares alan raymond shares martin whitaker shares ian ardill shares. authorise directors audit committee directors determine remuneration auditors. financial statements diurnal group plc _ annual report notice annual general meeting continued notes continued proxies continued. diurnal book plc_ annual report form proxy diurnal groups plc incorporated england wales registered number Annual general meeting iwe............................................................................... summarize:............................................................................................................................................................. full names block capitals............................................................................................................................................................................................................................... address blocks capitals.............................................................................................................................................................. address block capitals:.........................................................................................................................................................................................................................................................Posted by summarize:............................................................................................................................................................................................................................................. members named company appoint chairman meeting following person number shares relation name proxy proxy authorised act please refer explanatory note. financial statements diurnal group plc _ annual report form....................................................... financial statements summarize: _________________ continued notes, continued notes. and continue notes. Continued notes, and continued notes. and Continued notes.Article Continued Notes, Continued Notes.Article Continues BelowArticle Continued BelowArticle continues below.Article resumes.